Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2019

View Archived Issues

MYRF gene mutations linked to the development of nanophthalmos

VNLG-152R shows promising antitumor and antimetastatic activity in models of TNBC

Mutations in ADAMTSL1 are responsible for the pathogenesis of mandibular prognathism

Antiviral etravirine increases frataxin levels: a potential therapy for Friedreich's ataxia

NB-360 improves memory deficit in mice

Rhythm Pharmaceuticals provides update on setmelanotide development program

Potent new glucocorticoid reverses severe steroid-resistant asthma

Proteo initiates clinical development of subcutaneous Elafin

MR-35602, a novel triple-activity compound with promising activity in model of AD

Merck & Co. presents novel AD-specific tau monoclonal antibody, MAFT-0617

Alpelisib plus olaparib demonstrates promising activity and safety in phase I study

XenoTherapeutics initiates phase I study of Xeno-Skin

Targeting hair loss outside the follicle

No pain, emotional gain due to newly identified mutation

BioThera Solutions recruiting participants in phase I study of BAT-8003

Immunic patents IFN-gamma and IL-17 production inhibitors

GlaxoSmithKline divulges new MYC, p300 and CREBBP inhibitors

Hutchison MediPharma identifies IDH inhibitors

Chiesi Farmaceutici presents ROCK1 and ROCK2 inhibitors

FDA approves Mavenclad for relapsing-remitting and active secondary progressive MS

Cancer vaccine iNeo-Vac-P01 safe and beneficial in patients with solid tumors

BeiGene discloses PI3Kdelta inhibitors

Auris announces randomization of first dose cohort in phase Ib study of AM-201

Actinium advances antibody radiation conjugate research program with Astellas

FDA approves Duaklir for maintenance treatment of COPD

Poxel initiates phase IIa NASH program with PXL-770

Phio and Glycostem explore synergies of technologies for cancer immunotherapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...